KPV is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.
Status as of July 14, 2026
KPV is the final three-amino-acid tail of alpha-MSH, studied in preclinical models as an anti-inflammatory fragment rather than a proven drug. The larger hormone's pigment-signaling core is left out, so the interest in this tripeptide sits almost entirely in cell-culture and animal data, not human trials.
KPV is a synthetic lysine-proline-valine tripeptide matching residues 11 to 13 of alpha-MSH, examined in preclinical studies as an anti-inflammatory agent and not approved as a drug in any jurisdiction.
The peptide reads lysine-proline-valine from the amino end to the carboxyl end, joined by two peptide bonds. Proline in the center gives the backbone a built-in kink, and the literature ties that rigidity to how the molecule presents itself to binding partners.
KPV is a linear tripeptide of lysine, proline, and valine joined by two peptide bonds, with a central proline ring that reduces backbone flexibility.
Alpha-MSH is a 13-residue neuropeptide cut from proopiomelanocortin, the same precursor that yields ACTH and beta-endorphin. Its reputation rests on pigmentation, but the published record gives it a second, separate job as an endogenous anti-inflammatory mediator, and that second role is what made a fragment of it worth studying alone.
Alpha-MSH is a 13-amino-acid melanocortin neuropeptide cleaved from proopiomelanocortin that acts through the MC1R to MC5R receptors and serves both pigmentary and anti-inflammatory roles.
KPV is the last three residues of alpha-MSH, positions 11 through 13, drawn from the opposite end of the molecule from the HFRW stretch that drives pigment signaling. Leaving out that receptor core is the structural reason the fragment does not behave like the whole hormone, and why investigators treat it as the sequence's anti-inflammatory tail rather than a redesigned analog.
| Feature | HFRW core (positions 6-9) | KPV tail (positions 11-13) |
|---|---|---|
| Location in chain | central | C-terminal end |
| Function studied | melanocortin receptor pharmacophore, pigment signaling | anti-inflammatory activity |
| Relationship to KPV | excluded from the fragment | the fragment itself |
KPV is the naturally occurring C-terminal fragment of alpha-MSH at positions 11 to 13, truncated to exclude the central HFRW melanocortin pharmacophore that drives pigmentation.
The surviving activity is credited to a mechanism that looks different from the receptor-driven pigment signaling of the full hormone. Laboratory work reports that KPV can act inside the cell rather than at a surface melanocortin receptor, though the exact targets and how far the finding carries beyond cell and animal models are still unsettled.
The anti-inflammatory activity retained by KPV is attributed to receptor-independent, intracellular action, including reported interference with NF-kB signaling rather than melanocortin receptor binding.
Research-grade KPV is built synthetically, not pulled from tissue, and the standard route for a tripeptide is solid-phase peptide synthesis. The chain is assembled one residue at a time on a resin, then cleaved, purified, and checked against its expected mass before it is packaged as a powder.
KPV is produced by solid-phase peptide synthesis, purified by reversed-phase HPLC, and verified by mass spectrometry against its expected molecular weight near 342 daltons.
The clearest line between KPV and its relatives is functional, not a matter of size. Full-length alpha-MSH works through melanocortin receptors and drives pigment, appetite, and immune effects at once, while KPV carries only the anti-inflammatory emphasis of the tail and leaves the pigment machinery behind.
| Criterion | Alpha-MSH (full) | HFRW fragment | KPV fragment |
|---|---|---|---|
| Receptor binding | activates MC1R-MC5R | retains pigment pharmacophore | no meaningful receptor activation |
| Primary effect studied | pigment, appetite, immune | pigmentation | anti-inflammatory |
| Position in chain | full 1-13 | central 6-9 | C-terminal 11-13 |
KPV is the minimal C-terminal tail that carries alpha-MSH's anti-inflammatory character without the HFRW receptor core, separating it from the pigment-signaling melanocortin peptides.
KPV holds no marketing authorization from the FDA, the EMA, or any comparable regulator for any condition. In commerce it moves as a research chemical intended for laboratory work, which means therapeutic claims about it sit outside anything a regulator has reviewed, and the evidence stays dominated by preclinical studies.
KPV is not approved as a drug by the FDA, the EMA, or any major regulator, and is handled in commerce as a research chemical rather than a validated treatment.
As a bare tripeptide, KPV carries modest, well-defined chemistry: a molecular weight near 342 daltons and a basic, water-soluble character from its lysine side chain. Its practical weak point is stability, since short peptides like this are broken down quickly by peptidases, which is why research material is kept lyophilized and cold.
KPV has a molecular weight near 342 daltons and a basic, water-soluble profile, but its bare tripeptide structure leaves it susceptible to rapid peptidase degradation.
Educational use only. This article describes what the published scientific and clinical literature reports about KPV. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
